Medical News
Welcome to Medical News at Ecura Health
Medical knowledge is constantly evolving. New research studies, FDA approvals, safety alerts, clinical guidelines, and healthcare innovations are published every day, helping shape the future of medicine and patient care.
At Ecura Health, our goal is to help you stay informed by presenting the latest medical news in a clear, accurate, and easy-to-understand way. In this section, you’ll find physician-reviewed articles covering important healthcare developments, breakthrough treatments, medication safety updates, emerging technologies, public health announcements, and significant research findings that may affect your health and the care you receive.
Whether you’re interested in learning about newly approved medications, advances in obesity and diabetes treatment, FDA safety communications, preventive health recommendations, or promising medical discoveries, our news articles are designed to provide balanced, evidence-based information without sensational headlines or unnecessary medical jargon.
Explore our growing collection of medical news articles and stay up to date with the latest developments in healthcare through reliable, physician-reviewed reporting you can trust.
September 2026
A New Sunscreen Ingredient Has Finally Arrived in the U.S.: What to Know About Bemotrizinol
A new sunscreen ingredient has finally arrived in the United States. Bemotrizinol is a broad-spectrum UV filter that has been used in sunscreens in Europe and other countries for years but was not previously permitted in U.S. products. Following FDA authorization in 2026, sunscreens containing bemotrizinol are beginning to enter the U.S. market. Learn what makes this newer filter different, how it protects against UVA and UVB radiation, and whether you should consider changing your current sunscreen.
Read time: 7–8 minutes
Could Targeted Antibodies Lead to a Treatment for Alpha-Gal Syndrome?
Researchers have identified human antibodies that may help interrupt parts of the allergic response involved in alpha-gal syndrome. This article explains what the laboratory findings showed, why they are scientifically promising, and why they should not yet be mistaken for an available treatment.
Read time: 6 minutes
FDA Approves Camizestrant for ESR1-Mutated Advanced Breast Cancer | Ecura Health
The FDA has approved a new mutation-guided treatment approach for a specific group of adults with advanced breast cancer. This article explains who may qualify, how blood testing guides treatment, what the clinical trial found, and why accelerated approval still carries important uncertainty.
Read time: 7 minutes
Targeted Ablation Improved Rhythm Control in Selected Adults With Persistent AF | Ecura Health
A new randomized trial tested a more individualized catheter-ablation strategy for selected adults with persistent atrial fibrillation. This article explains what low-voltage zones are, how the procedure differed from standard pulmonary vein isolation, what improved, and what the study cannot yet establish.
Read time: 7 minutesAugust 2026
A New Pancreatic Cancer Treatment Nearly Doubled Survival: What to Know About Daraxonrasib
A new experimental drug called daraxonrasib is showing promising results for people with previously treated metastatic pancreatic cancer. In a Phase III clinical trial, patients receiving daraxonrasib had a median overall survival of 13.2 months compared with 6.7 months for patients receiving standard chemotherapy. The oral medication works by targeting RAS signaling, a pathway involved in more than 90% of pancreatic ductal adenocarcinomas. Daraxonrasib is not yet FDA approved, but eligible patients may be able to access it through an expanded-access program while FDA review and additional research continue.
Read time: 7–8 minutes
Candida Auris: What to Know About This Drug-Resistant Fungus
Candida auris (C. auris) is an emerging, drug-resistant fungus that is spreading in healthcare facilities and can cause serious infections in medically vulnerable patients. Unlike the Candida that commonly causes vaginal yeast infections, C. auris primarily affects people who are hospitalized, live in certain long-term care facilities, or require complex medical care. Its ability to survive on surfaces, spread between patients, and resist common antifungal medications has made it a growing public health concern. Learn who is most at risk, how it spreads, why it can be difficult to treat, and whether healthy people should be concerned.
Read time: 6–7 minutes
Cyclosporiasis: When Persistent Diarrhea May Be More Than a Stomach Bug
Cyclosporiasis is an intestinal infection caused by the microscopic parasite Cyclospora cayetanensis, typically acquired through contaminated food or water. Unlike many common stomach bugs, it can cause watery diarrhea that lasts for weeks or improves only to return again. With cases often increasing during the warmer months and outbreaks linked to fresh produce, knowing the warning signs can help you recognize when persistent diarrhea deserves medical attention. Learn how Cyclospora spreads, how it is diagnosed and treated, and when you should consider getting tested.
Read time: 5–6 minutesJuly 2026
You're Not Too Young for Rectal Cancer
Rectal cancer is no longer considered a disease that only affects older adults. Cases in people under 50 have been steadily rising, often leading to delayed diagnoses because symptoms are mistaken for hemorrhoids or other common conditions. Learn why this trend is concerning, the warning signs you should never ignore, and when it's time to seek medical evaluation.
Estimated reading time: 6 minutes
New Study Links Vitamins A and D to Better Lung Health in People With Asthma
Can vitamins A and D improve asthma? A new study found that people with asthma who had higher levels of these vitamins tended to have better lung function, with vitamin D also linked to healthier lung aging in adults. Learn what the research found, what it means, and why experts say it's too early to recommend supplements for everyone.
Estimated Reading Time: 3 minJune 2026
FDA Warns About Unapproved GLP-1 Weight Loss Drugs: What Patients Need to Know
The FDA is warning consumers about the risks of unapproved GLP-1 weight loss medications, including compounded and counterfeit products. Learn what these warnings mean, how to recognize potential red flags, and how to protect yourself when obtaining medications like semaglutide and tirzepatide.
Estimated reading time: 5 minutes
Retatrutide Delivers Remarkable Weight Loss in Landmark Phase 3 Trial
Retatrutide, an investigational weight loss medication, has produced some of the most impressive results ever seen in an obesity clinical trial, with participants losing nearly 30% of their body weight. Learn how this next-generation therapy works, what the latest research shows, and why experts believe it could reshape the future of obesity treatment.
Estimated reading time: 5 minutes